Literature DB >> 21775057

Prolactin increases survival and migration of ovarian cancer cells: importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists.

Dunyong Tan1, Kuanhui E Chen, Teresa Khoo, Ameae M Walker.   

Abstract

Variably-spliced prolactin receptors (PRLRs) and PRL are expressed by the ovarian cancer cell lines, TOV-112D, OV-90 and TOV-21G. Incubation in the PRLR antagonists, G129R- or S179D-PRL, or anti-PRL reduced cell number, indicating a functional autocrine PRL growth loop. Added PRL promoted, and the antagonists decreased, cell migration. When cells were stressed, added PRL decreased apoptosis and increased survival, and the antagonists had the opposite effect. Cells expressing higher long:short PRLR ratios had increased growth, survival and migration in response to PRL. Results suggest that PRLR antagonists may be therapeutically beneficial in ovarian cancer.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21775057     DOI： 10.1016/j.canlet.2011.06.014

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  15 in total

Review 1.  Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications.

Authors:  Tova M Bergsten; Joanna E Burdette; Matthew Dean
Journal:  Cancer Lett       Date:  2020-02-15       Impact factor: 8.679

2.  Circulating prolactin levels and risk of epithelial ovarian cancer.

Authors:  Tess V Clendenen; Alan A Arslan; Anna E Lokshin; Mengling Liu; Eva Lundin; Karen L Koenig; Franco Berrino; Goran Hallmans; Annika Idahl; Vittorio Krogh; Annekatrin Lukanova; Adele Marrangoni; Paola Muti; Brian M Nolen; Nina Ohlson; Roy E Shore; Sabina Sieri; Anne Zeleniuch-Jacquotte
Journal:  Cancer Causes Control       Date:  2013-02-03       Impact factor: 2.506

3.  Impact of subdomain D1 of the short form S1b of the human prolactin receptor on its inhibitory action on the function of the long form of the receptor induced by prolactin.

Authors:  J-H Kang; S A Hassan; P Zhao; C H Tsai-Morris; M L Dufau
Journal:  Biochim Biophys Acta       Date:  2014-04-13

4.  GHR/PRLR Heteromultimer Is Composed of GHR Homodimers and PRLR Homodimers.

Authors:  Ying Liu; Yue Zhang; Jing Jiang; Peter E Lobie; Ramasamy Paulmurugan; John F Langenheim; Wen Y Chen; Kurt R Zinn; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2016-03-22

5.  Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.

Authors:  Yunfei Wen; Behrouz Zand; Bulent Ozpolat; Miroslaw J Szczepanski; Chunhua Lu; Erkan Yuca; Amy R Carroll; Neslihan Alpay; Chandra Bartholomeusz; Ibrahim Tekedereli; Yu Kang; Rajesha Rupaimoole; Chad V Pecot; Heather J Dalton; Anadulce Hernandez; Anna Lokshin; Susan K Lutgendorf; Jinsong Liu; Walter N Hittelman; Wen Y Chen; Gabriel Lopez-Berestein; Marta Szajnik; Naoto T Ueno; Robert L Coleman; Anil K Sood
Journal:  Cell Rep       Date:  2014-04-03       Impact factor: 9.423

6.  Human metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment.

Authors:  Elahu G Sustarsic; Riia K Junnila; John J Kopchick
Journal:  Biochem Biophys Res Commun       Date:  2013-10-14       Impact factor: 3.575

7.  The Effects of 20-kDa Human Placental GH in Male and Female GH-deficient Mice: An Improved Human GH?

Authors:  Edward O List; Darlene E Berryman; Reetobrata Basu; Mathew Buchman; Kevin Funk; Prateek Kulkarni; Silvana Duran-Ortiz; Yanrong Qian; Elizabeth A Jensen; Jonathan A Young; Gozde Yildirim; Shoshana Yakar; John J Kopchick
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

8.  Small cell ovarian carcinoma: genomic stability and responsiveness to therapeutics.

Authors:  Lisa F Gamwell; Karen Gambaro; Maria Merziotis; Colleen Crane; Suzanna L Arcand; Valerie Bourada; Christopher Davis; Jeremy A Squire; David G Huntsman; Patricia N Tonin; Barbara C Vanderhyden
Journal:  Orphanet J Rare Dis       Date:  2013-02-21       Impact factor: 4.123

9.  Prolactin receptor in primary hyperparathyroidism--expression, functionality and clinical correlations.

Authors:  Felix Haglund; Ming Lu; Vladana Vukojević; Inga-Lena Nilsson; Adam Andreasson; Mensur Džabić; Robert Bränström; Anders Höög; C Christofer Juhlin; Catharina Larsson
Journal:  PLoS One       Date:  2012-05-11       Impact factor: 3.240

10.  Prolactin and Risk of Epithelial Ovarian Cancer.

Authors:  Cassandra A Hathaway; Megan S Rice; Mary K Townsend; Susan E Hankinson; Alan A Arslan; Julie E Buring; Göran Hallmans; Annika Idahl; Laura D Kubzansky; I-Min Lee; Eva A Lundin; Patrick M Sluss; Anne Zeleniuch-Jacquotte; Shelley S Tworoger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-07-08       Impact factor: 4.254
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.